Traders should monitor the company's ability to monetize its functional skincare business and manage its R&D expenses, as the recent revenue growth is offset by significant losses. The $14M capital raise provides runway but the high R&D spend suggests continued investment phase.
Price Chart
Executive Summary
Meiwu Technology Co Ltd reported a significant revenue increase to $7.08M in 2025 from $158K in 2024, driven by its strategic shift to functional skincare. However, the company incurred a net loss of $18.19M, primarily due to $9.83M in asset impairment losses and $2.69M in R&D expenses. The company also raised $14M in a March 2026 registered direct offering, which will be used for working capital and potential acquisitions.
Key Facts
- Revenue increased from $158,485 in 2024 to $7,081,133 in 2025, driven by the new functional skincare business
- Net loss was $18,192,303 in 2025 compared to net income of $5,114,684 in 2024
- Asset impairment loss was $9,834,584 in 2025, up from $1,449,371 in 2024
- Research and development expenses increased to $2,685,201 in 2025 from $689 in 2024
- The company raised $14 million in a registered direct offering in March 2026
Financial Impact
The company incurred a net loss of $18.19M in 2025, primarily due to $9.83M in asset impairment losses and $2.69M in R&D expenses
Risk Factors
- High asset impairment losses indicate potential issues with previous investments
- Significant increase in R&D expenses without corresponding revenue growth
- Reliance on new functional skincare business which may not be sustainable
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 12 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001493152-26-017159 |
| Exhibit: ex11-1.htm | 0001493152-26-017159 |
| Exhibit: ex12-1.htm | 0001493152-26-017159 |
| Exhibit: ex12-2.htm | 0001493152-26-017159 |
| Exhibit: ex8-1.htm | 0001493152-26-017159 |
| Exhibit: ex15-1.htm | 0001493152-26-017159 |
| Exhibit: ex13-2.htm | 0001493152-26-017159 |
| Exhibit: ex13-1.htm | 0001493152-26-017159 |
| Exhibit: ex15-2.htm | 0001493152-26-017159 |
| Document: 0001493152-26-017159-index-headers.html | 0001493152-26-017159 |
| Document: 0001493152-26-017159-index.html | 0001493152-26-017159 |
| Document: 0001493152-26-017159.txt | 0001493152-26-017159 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 5w ago | 6-K | $2.52 $2.16 | ▼ −14.29% | ▼ −16.35% | $2.09 (−17.06%) |
May 11, 2026 24w ago | 3 | $3.21 $3.51 | ▲ +9.35% | ▲ +11.07% | $2.09 (−34.89%) |
May 8, 2026 24w ago | 6-K | $3.20 $3.57 | ▼ −11.56% | ▼ −11.87% | $2.09 (+34.69%) |
Apr 17, 2026 27w ago | 20-F | $5.87 $3.22 | ▼ −45.14% | ▼ −50.52% | $2.09 (−64.40%) |
Feb 25, 2026 34w ago | EFFECT | $153.00 $11.20 | ▼ −92.68% | ▼ −87.44% | $2.09 (−98.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers